Report me for selling fake medicine? Why are you crying when your illness relapses?

Such an expensive drug price will definitely make some groups unable to afford this medicine, which will naturally greatly affect the real market demand, and it is impossible for the market to be several times larger than the Chinese market.

After taking these two aspects into consideration, Novartis' order volume is relatively conservative.

1000 million boxes in the first year and no less than 1500 million boxes thereafter. This is a relatively safe sales target.

If the overseas pricing is the same as that in China, Anna is confident that she can double or triple the sales volume.

But there was no way. The price difference between the two markets was too big, and the demand would naturally change accordingly. She didn't dare to take the risk.

If there are too many orders now and we can’t sell them, we will suffer a huge loss.

……

……

"no problem,"

Chen Xuan nodded and agreed immediately.

He is quite satisfied with the sales volume.

Although the sales volume is similar to that of the Chinese market, the profits are different.

In the first year, there were 1000 million boxes, and based on the factory price of 5000 yuan per box, that was 500 billion yuan. In the following year, there were 1500 million boxes, and the revenue reached 750 billion yuan.

If calculated over four years, that would be 2750 billion in revenue.

As for profits, there is no need to mention that the profit margin in overseas markets is much higher than that in the Chinese market.

This is just a relatively conservative sales estimate. The actual sales volume should be higher than this number, so the revenue and profit will only be higher than this estimate.

The gap between the two markets is indeed very large, especially when the price difference is particularly large, the gap will only be more exaggerated.

Chinese market plus overseas market.

The effective drug for lung cancer has just been launched on the market and has already generated more than 3000 billion in revenue.

This can indeed be regarded as a sales myth in the pharmaceutical industry. Except for some special cases, it is almost impossible for other drugs to achieve this kind of revenue when they are first launched on the market.

If this revenue were to be exposed, it would probably shock the whole world.

Even though everyone knows that the market for lung cancer-specific drugs is huge, the high level of attention it has received before shows how great the demand for this drug is.

But it still seems incredible to everyone that the lung cancer drug can generate more than 3000 billion in revenue just after it was launched on the market.

Judging from the current situation, the lung cancer specific drug has the potential to become the world's top medicine.

Of course, the premise is that Antai Pharmaceutical Group’s subsequent new drugs do not show greater potential, otherwise it is difficult to say.

But what is certain is that the title of Global Medicine King will definitely belong to Antai Pharmaceutical Group.

"Have you decided on the retail price?" Chen Xuan had no objection to Novartis' order volume.

This order is very reasonable and relatively conservative, but not small either. 1000 million boxes in the first year is already very good.

For many best-selling drugs, in their first year, they don’t even sell 1/10 of 1000 million boxes, which is already considered a very strong order.

Therefore, he is more concerned about the retail price of the lung cancer drug, which is a point on which the two parties have not yet reached a formal agreement.

If the retail price is beyond his acceptable range, he may have to look for new partners.

After all, if the retail price is ridiculously high, there will definitely not be much sales overseas. Even if it is handed over to Novartis for agency, it will only waste such a large market.

The factory price of the lung cancer drug is already very high. If Novartis continues to raise the price, the final sales volume will definitely be very low. Only a very small number of wealthy people can afford this drug.

Therefore, Chen Xuan needs to understand this now so that he can decide whether to cooperate with Novartis.

He can allow Novartis to make money. Of course, the purpose of doing business is to make money. You can't just make money for yourself and ask others to work for you for free.

Of course, he would never have such an idea, but he couldn't make too much money. If he raised the price too high, it would affect the sales of the lung cancer drug and his income.